Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3313-3323

  Galanis, Evanthia ^a   Hersh, E M ^a   Stopeck, A T ^a   Gonzalez, R ^a   Burch, P ^a   Spier, C ^a   Akporiaye, E T ^a   Rinehart, J J ^a   Edmonson, J ^a   Sobol, R E ^a   Forscher, C ^a   Sondak, V K ^a   Lewis, B D ^a   Unger, E C ^a   O'Driscoll, M ^a   Selk, L ^a   Rubin, J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CD8 ANTIGEN; GENE PRODUCT; GLYCEROL; INTERLEUKIN 2; LEUVECTIN; PLASMID DNA; UNCLASSIFIED DRUG; VCL 1102;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOPSY; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; GENE TRANSFER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRATUMORAL DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0032886544     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3313     Document Type: Article

References (32)

1. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492, 1985
2. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271:907-913, 1994
3. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696, 1995
4. Proleukin. Emeryville, CA, Chiron Corporation, 1998 (package insert)
5. Golumbek PT, Lazenby AJ, Levitsky HI, et al: Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713-716, 1991
6. Gansbacher B, Zeir K, Daniels B, et al: Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217-1224, 1990
7. Blankenstein T, Qin ZH, Uberla K, et al: Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 173:1047-1052, 1991
8. Colombo MP, Ferrari G, Stoppacciaro A, et al: Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 173:889-897, 1991
9. Fearon ER, Pardoll DM, Itaya T, et al: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-403, 1990
10. Zier KS, Gansbacher B: IL-2 gene therapy of solid tumors: An approach for the prevention of signal transduction defects in T cells. J Mol Med 74:127-1-34, 1996
11. Parker SE, Khatibi S, Margalith M, et al: Plasmid DNA gene therapy: Studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther 3:175-185, 1996
12. Saffran DC, Horton HM, Yankauckas MA, et al: Immunotherapy of established tumors in mice by intratumoral injection of IL-2 plasmid DNA: Induction of CD8+ T cell immunity. Cancer Gene Ther 5:321-330, 1998
13. Parker SE, Vahlsing HL, Serfilippi LM, et al: Cancer gene therapy using plasmid DNA: Safety evaluation in rodents and non-human primates. Hum Gene Ther 6:575-590, 1995
14. Stopeck AT, Hersh EM, Brailey JL, et al: Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes. Cancer Gene Ther 5:119-126, 1998
15. Spier CM, Grogan TM, Fielder K, et al: Immunophenotypic profiles in well-differentiated lymphoproliferative disorders, with emphasis on small lymphocytic lymphoma. Hum Pathol 17:1126-1136, 1986
16. Parker SE, Khatibi S, Margalith M, et al: Antitumor efficacy of plasmid DNA encoding the human IL-2 gene. Cancer Gene Ther 3:175-185, 1996
17. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-913, 1994
18. Hawkins MJ: Interleukin-2 antitumor and effector cell responses. Semin Oncol 20:52-59, 1993
19. Rosenberg SA: The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180-199, 1992
20. Belli F, Arienti F, Sule-Suso J, et al: Active immunization of metastatic melanoma patients with interleukin-2 transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability. Cancer Immunol Immunother 44:197-203, 1997
21. Ellen KAO, O'Rourke MGE, Johnson GR, et al: A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 44:10-20, 1997
22. Simons JW, Jaffee EM, Weber CE, et al: Bioactivity of autologous irradiated renal cell carcinoma colony-stimulating factor gene transfer. Cancer Res 57:1537-1546, 1997
23. Abdel-Wahab Z, Weltz C, Hester D, et al: A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells. Cancer 80:401-412, 1997
24. Hersh EM, Stopeck AT: Advances in the biological therapy and gene therapy of malignant disease. Clin Cancer Res 3:1623-1629, 1997
25. Vogelzang NJ, Sudakoff G: Clinical experience in phase I and phase II testing of direct intratumoral administration with Allovectin-7: A gene-based immunotherapeutic agent. Proc Am Soc Clin Oncol 15:235, 1996 (abstr)
26. Mani S, Todd MB, Katz K, et al: Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 154:35-40, 1995
27. Chen Q, Daniel V, Maher DW, et al: IL-10 is produced by melanoma cells and may have a role in immunosuppression mediated by melanoma. Int J Cancer 56:1-6, 1994
28. Nabel GJ, Nabel EG, Yang ZY, et al: Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A 90:11307-11311, 1993
29. Young RC: Metastatic renal cell carcinoma: What causes occasional dramatic regressions? N Engl J Med 338:1305-1306, 1998
30. Oliver RTD: Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now. Br J Cancer 77:1318-1320, 1998
31. Rubin J, Galanis E, Pitot HC, et al: Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B8. Gene Ther 4:419-425, 1997
32. Stopeck AT, Hersh EM, Akporiaye ET, et al: Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 15:341-349, 1997